Digital PCR Sales Contribute to Record Q4 Revenues for Bio-Rad's Life Sciences Segment | GenomeWeb

Bio-Rad this week reported record revenues of $204.2 million for its Life Sciences segment in the fourth quarter driven by strong sales of nucleic acid amplification reagents, process media, and sales of its QX100 digital PCR system and associated products, company executives said.

The Life Sciences segment revenues were a 2.7 percent increase over the prior-year period, or a 3.7 percent increase excluding foreign currency effects, the company said. On a geographic basis, sales in Latin America and the US were especially robust, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.